Dr. Richard Walker Discusses Sermorelin Growth Hormone Releasing Hormone
19.4 هزار بار بازدید -
6 سال پیش
-
For more information about Sermorelin,
For more information about Sermorelin, please contact www.DefyMedical.com. Transcript: In 1970s and 1980s there was a major shift in the focus of neuroendocrinology to understand how the brain controlled the pituitary. There were two major players in that effort. One of them was Roger Guillemin and the other one was Andrew Schally. They were quite competitive and there was a big race to find out who would get the Nobel prize basically. It was contingent upon finding this mysterious peptide that they were having great trouble doing because of its rarity. That hormone was a growth hormone releasing hormone. Now, let me give you a brief background on that. Guillemin, who was working at that time in San Diego in the University of California there, used a traditional approach of taking animals and extracting tissues. But don't forget, I told you already that growth hormone and its releasing factors are species specific so you had to have human tissue. To get enough tissue from the brain of even from cadavers, was impossible to get enough to sequence the molecule to identify what it actually was so that we could reproduce it, so that we could make it. Now, to give you some example of the size of the molecules, the growth hormone molecule itself that's produced in the pituitary is 181 amino acids which may not mean too much but that's a pretty big molecule. It's folded all up. It's compact. The molecules in the brain that control that are very small, relatively small. One of them, the one that Guillemin was looking for and Schally were looking for first, the growth hormone releasing hormone, turned out to be 44 amino acids but they couldn't get it out of people and yet they couldn't take it from animals because animals' growth hormone releasing hormones are not species specific for humans.Fortuitously, there was a situation in the Midwest where a colleague of mine, Larry
Frillman had a patient who was an acromegalic patient which means he was a giant. He was getting stimulated by excessive amounts of growth hormone. He also had a pancreatic tumor. He had pancreatic cancer. There was a question about why is he growing so big and what happened was that this guy Frillman and his colleagues took some of that tissue and they sent it to Guillemin in San Diego and also distributed to other people. The reason the patient with pancreatic cancer was a giant is because that tissue was producing growth hormone releasing hormone which normally is only produced in the brain but this tissue was making that. Now, subsequently, it's been known that there are cancers that produce some of these hormones and that was fortunately one of them because now they had a source, a big enough source, to identify the 44 amino acid sequence that constituted GHRH. One of Guillemin's postdocs by the name of Bill Weinberg was charged with the job of trying to figure out how much of that big molecule ... Well, 44 amino acid molecule, it wasn't that big, not as big as growth hormone ... how much of that molecule was necessary to stimulate growth hormone. It turned out that that molecule only had to be 29 amino acids long, the first sequence, the first 29 amino acids of that 44 amino acid sequence, was the active ingredient. At that point, it was patented by UC San Diego and then bought by Sandoz, another pharmaceutical company, and made into a product called Geref. Geref was then used to diagnose growth hormone deficiency in kids that came needing growth hormone. You had to do a diagnostic before you could prescribe the growth hormone. So this stuff was then called Geref but it's generic name was sermorelin. What happened was Sandoz was putting out both Geref and also its own growth hormone. Now, growth hormone when you administer to growth hormone deficient children grow very fast and when you give them the stimulator of their own growth hormone, they grow slower. So patients ... The parents of these children wanted faster results so they bought more of the Saizen or the growth hormone, than they did the sermorelin. So the product was dropped by Sandoz and became open market. Nowadays it's available to everyone through your physician, to be used for stimulating the pituitary gland to producing your own growth hormone rather than injecting growth hormone.
In closing I'm going to tell you about another approach that was being taken at the same time. It was a chemical approach used by an associate of Schally. By the way, Schally and Guillemin both got the Nobel prize. They split it for discovering the structure of GHRH or what became sermorelin. Schally's associate, whose name was Cy Bowers, Cyril Bowers, was a chemist. He wasn't a physician but he had some ideas that if you take very small molecules of the brain, he would work backward and try to synthesize growth hormone releasing hormone by modifying the structure of a small molecule called metencephalon. It's a natural molecule in the brain. Truncated due to word limits.
Frillman had a patient who was an acromegalic patient which means he was a giant. He was getting stimulated by excessive amounts of growth hormone. He also had a pancreatic tumor. He had pancreatic cancer. There was a question about why is he growing so big and what happened was that this guy Frillman and his colleagues took some of that tissue and they sent it to Guillemin in San Diego and also distributed to other people. The reason the patient with pancreatic cancer was a giant is because that tissue was producing growth hormone releasing hormone which normally is only produced in the brain but this tissue was making that. Now, subsequently, it's been known that there are cancers that produce some of these hormones and that was fortunately one of them because now they had a source, a big enough source, to identify the 44 amino acid sequence that constituted GHRH. One of Guillemin's postdocs by the name of Bill Weinberg was charged with the job of trying to figure out how much of that big molecule ... Well, 44 amino acid molecule, it wasn't that big, not as big as growth hormone ... how much of that molecule was necessary to stimulate growth hormone. It turned out that that molecule only had to be 29 amino acids long, the first sequence, the first 29 amino acids of that 44 amino acid sequence, was the active ingredient. At that point, it was patented by UC San Diego and then bought by Sandoz, another pharmaceutical company, and made into a product called Geref. Geref was then used to diagnose growth hormone deficiency in kids that came needing growth hormone. You had to do a diagnostic before you could prescribe the growth hormone. So this stuff was then called Geref but it's generic name was sermorelin. What happened was Sandoz was putting out both Geref and also its own growth hormone. Now, growth hormone when you administer to growth hormone deficient children grow very fast and when you give them the stimulator of their own growth hormone, they grow slower. So patients ... The parents of these children wanted faster results so they bought more of the Saizen or the growth hormone, than they did the sermorelin. So the product was dropped by Sandoz and became open market. Nowadays it's available to everyone through your physician, to be used for stimulating the pituitary gland to producing your own growth hormone rather than injecting growth hormone.
In closing I'm going to tell you about another approach that was being taken at the same time. It was a chemical approach used by an associate of Schally. By the way, Schally and Guillemin both got the Nobel prize. They split it for discovering the structure of GHRH or what became sermorelin. Schally's associate, whose name was Cy Bowers, Cyril Bowers, was a chemist. He wasn't a physician but he had some ideas that if you take very small molecules of the brain, he would work backward and try to synthesize growth hormone releasing hormone by modifying the structure of a small molecule called metencephalon. It's a natural molecule in the brain. Truncated due to word limits.
6 سال پیش
در تاریخ 1397/11/09 منتشر شده
است.
19,456
بـار بازدید شده